Merck Millipore Announces Incoming CEO and President
News Apr 15, 2014
Dr. Batra will assume leadership effective May 15, 2014 and be based at the company’s U.S. headquarters in Massachusetts.
“As a global leader in the Life Sciences industry, I am very humbled and excited to be a part of Merck Millipore team and look forward to serving our customers globally,” Dr. Batra said. “As a former researcher who personally utilized the strong differentiated products that Merck Millipore offers, I have watched this organization develop over the past several years, and look forward to further building upon that success to bring continued value to our customers and other stakeholders.”
Dr. Batra comes to Merck Millipore from the Consumer Health division of Merck KGaA, where he successfully grew the business in established and emerging markets. He previously worked at Novartis Vaccines & Diagnostics, where he was Head of Global Public Health and Market Access. Prior to that, he served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
Dr. Batra started his career as a research engineer at Merck & Co. In 2001, he joined McKinsey where he worked across the healthcare, consumer and nonprofit sectors as a senior engagement manager. In 2004, he was appointed global Brand Director for the Wound Care Franchise at Johnson & Johnson, before joining Novartis in 2006.
Dr. Batra is a member of the WSMI (World Self Medication Industry) and the Chair of the Food Supplements Committee of the AESGP (Association of the European Self-Medication Industry).
He holds a Ph.D. in chemical engineering from Princeton University and a bachelor’s degree in chemical engineering from the University of Delaware.
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE